Epstein Secrets

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright C' 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communicatio

hould discuss their LDL cholesterol with their physician and consider whether they need to lower it further." Reference Sabatine MS. Giugliano RP, Keech AC, et al. N Engl J Med. 2017;doi:NEJMoa1615664 http://www.nejm.orq/doUpdf/10.1056/NEJMoa 1615664 Sabatine M. Primary Results of the Further Cardiovas

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright @ 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communication

hould discuss their LDL cholesterol with their physician and consider whether they need to lower it further." Reference Sabatine MS, Giugliano RP, Keech AC, et al. N Eng! J Med. 2017;doi:NEJMoa1615664 http://www.nejm.orgidoi/pdf/10.1056/NEJMoa1615664 Sabatine M. Primary Results of the Further Cardiovas

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright O 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communication

hould discuss their LDL cholesterol with their physician and consider whether they need to lower it further." Reference Sabatine MS, Giugliano RP, Keech AC, et al. N Eng! J Med. 2017;doi:NEJMoa1615664 http://www.ne m.orgidoi/pdftl0.1056/NEJMoa1615664 Sabatine M. Primary Results of the Further Cardiovas